[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580853":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":16,"locations":7,"responsibleParty":26,"collaborators":7,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":30,"sex":36,"minAge":37,"maxAge":7,"enrollmentInfo":38,"targetDuration":41,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":52,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":7},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",null,[9,13],{"name":10,"affiliation":11,"role":12},"Quentin Le Hingrat, DR","Bichat-Claude Bernard University Hospital, Paris, AP-HP.Nord","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":15,"role":12},"Constance Delaugerre, PR","Service de Virologie Hôpital Saint-Louis, AP-HP.Nord 1 avenue Claude Vellefaux, 75010 Paris",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Mariam GHARIB","CONTACT","0144236442","mariam.gharib@inserm.fr",{"name":23,"role":19,"phone":24,"phoneExt":7,"email":25},"Quentin Le Hingrat","+33 1 40 25 88 06","quentin.lehingrat@aphp.fr",{"type":27,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100580853","prevalence-of-drug-resistant-hiv-1-strains-in-patients-experiencing-virologic-failure-multivir2025-100580853",false,"NCT06842706","Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)","Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure.(MULTIVIR2025)","MULTIVIR2025","Inclusion Criteria:\n\n* Patient (male or female) 18 years of age or older.\n* Patient who has given his or her consent to participate in the study.\n* Patient on antiretroviral therapy for at least six months, with a plasma viral load (VL) greater than 50 copies\u002FmL on at least two consecutive measurements.\n\nExclusion Criteria:\n\n* Patients opposed to the use of their data.","ALL","18 Years",{"count":39,"type":40},800,"ESTIMATED","1 Day","OBSERVATIONAL","In this cross-sectional, national and multicenter study, the main objective is to determine the prevalence of multi-drug resistant viruses (i.e., viruses that are resistant or possibly resistant to at least one antiretroviral drug from four different therapeutic classes: NRTI, NNRTI, PI, INSTI) among people with HIV 1 (PWH) experiencing virological failure.",[45],"HIV Infection",[47,48,49,50,51],"HIV","drug resistance","antiretrovirals","multi-drug resistant","virological failure","NOT_YET_RECRUITING","2025-02-24",{"date":55,"type":56},"2025-02-26","ACTUAL",{"date":58,"type":40},"2025-04",{"date":60,"type":40},"2026-03",{"name":5,"class":6}]